"Dr. Madduri On SWOG S0777 In Multiple Myeloma" - Deepu Madduri, MD
Deepu Madduri, MD, assistant professor of medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai, discusses evidence supporting the use of a triplet regimen versus a doublet regimen in elderly and transplant ineligible patients with multiple myeloma. According to results from SWOG S0777, the triplet regimen bortezomib, lenalidomide, and dexamethasone was better than the previous standard of care, lenalidomide and dexamethasone. Both the overall survival and progression-free survival were improved with RVD, said Dr. Madduri. The triplet regimen is now used at a lower dose, according to Dr. Madduri.
- Deepu Madduri, MD, Assistant Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai